Drug name - Nexlizet

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(3 years from now)

EP1597223A2 ESPERION THERAPS INC Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses
Dec, 2023

(1 year, 2 months from now)

EP1597223B1 ESPERION THERAPS INC Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses
Dec, 2023

(1 year, 2 months from now)

EP2402300A1 ESPERION THERAPS INC Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses
Dec, 2023

(1 year, 2 months from now)

EP2402300B1 ESPERION THERAPS INC Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses
Dec, 2023

(1 year, 2 months from now)

EP2404890A1 ESPERION THERAPS INC Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses
Dec, 2023

(1 year, 2 months from now)

EP2404890B1 ESPERION THERAPS INC Hydroxyl Compounds And Compositions For Cholesterol Management And Related Uses
Dec, 2023

(1 year, 2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497301 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US10118881 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US9000041 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US10941095 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US9624152 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses Dec, 2023

(1 year, 2 months from now)

US10912751 ESPERION THERAPS INC Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease Mar, 2036

(13 years from now)

Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient

Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; A method of treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease by decreasing the level of ldl-c using a fixed dose combination of 180 mg bempedoic acid and 10 mg ezetimibe

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
180MG;10MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.